Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHumanized mAb targeting IgG1 serum amyloid P component (SAP; APCS)
Molecular Target Serum amyloid P component (SAP) (APCS)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAmyloidosis
Indication DetailsTreat systemic amyloidosis
Regulatory Designation U.S. - Orphan Drug (Treat systemic amyloidosis);
EU - Orphan Drug (Treat systemic amyloidosis)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today